EU Approves Bristol-Myers Squibb’s Daklinza

Drug Industry Daily
A A
Bristol-Myers Squibb says it will soon start marketing its hepatitis C drug Daklinza in the European Union, following approval Wednesday.

To View This Article:

Login

Subscribe To Drug Industry Daily